JP2022514179A5 - - Google Patents
Info
- Publication number
- JP2022514179A5 JP2022514179A5 JP2021523958A JP2021523958A JP2022514179A5 JP 2022514179 A5 JP2022514179 A5 JP 2022514179A5 JP 2021523958 A JP2021523958 A JP 2021523958A JP 2021523958 A JP2021523958 A JP 2021523958A JP 2022514179 A5 JP2022514179 A5 JP 2022514179A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody molecule
- nucleotide sequence
- seq
- antibody
- plasmid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18203996 | 2018-11-01 | ||
| EP18203996.6 | 2018-11-01 | ||
| PCT/EP2019/080003 WO2020089473A2 (en) | 2018-11-01 | 2019-11-01 | Novel agonistic antibody molecules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022514179A JP2022514179A (ja) | 2022-02-10 |
| JP2022514179A5 true JP2022514179A5 (https=) | 2022-10-26 |
| JP7664833B2 JP7664833B2 (ja) | 2025-04-18 |
Family
ID=64109795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523958A Active JP7664833B2 (ja) | 2018-11-01 | 2019-11-01 | 新規アゴニスト抗ｔｎｆｒ２抗体分子 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12139547B2 (https=) |
| EP (1) | EP3873935A2 (https=) |
| JP (1) | JP7664833B2 (https=) |
| KR (1) | KR20210087466A (https=) |
| CN (3) | CN121248780A (https=) |
| AU (1) | AU2019370999A1 (https=) |
| BR (1) | BR112021008007A2 (https=) |
| CA (1) | CA3117756A1 (https=) |
| IL (1) | IL282713A (https=) |
| MX (2) | MX2021005151A (https=) |
| WO (1) | WO2020089473A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220193196A1 (en) * | 2019-05-28 | 2022-06-23 | The Walter And Eliza Hall Institute Of Medical Research | Methods for Modulating T Cell Activation |
| TWI878554B (zh) | 2020-06-12 | 2025-04-01 | 大陸商南京維立志博生物科技股份有限公司 | 結合ｔｎｆｒ２的抗體及其用途 |
| KR20230034367A (ko) * | 2020-07-02 | 2023-03-09 | 바이오로직 디자인 리미티드 | 항-종양 괴사 인자 수용체 (tnfr2) 항체 및 그 용도 |
| EP4067381A1 (en) * | 2021-04-01 | 2022-10-05 | Julius-Maximilians-Universität Würzburg | Novel tnfr2 binding molecules |
| CN117836325A (zh) * | 2021-06-22 | 2024-04-05 | 盛禾(中国)生物制药有限公司 | 一种抗tnfr2抗体及其制备方法和应用 |
| CN115925929A (zh) | 2021-09-22 | 2023-04-07 | 上海康岱生物医药技术股份有限公司 | 抗tnfr2单克隆抗体及其应用 |
| WO2023154799A1 (en) | 2022-02-14 | 2023-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Combination immunotherapy for treating cancer |
| CA3256751A1 (en) * | 2022-05-26 | 2023-11-30 | Pfizer Inc. | Anti-TNFR2 antibodies and their methods of use |
| JP2026503077A (ja) * | 2023-01-09 | 2026-01-27 | オデッセイ セラピューティクス，インコーポレイテッド | 抗ｔｎｆｒ２抗原結合タンパク質及びその使用 |
| CN121013905A (zh) * | 2023-03-31 | 2025-11-25 | 艾菲赛尔治疗株式会社 | 已经引入至编码特异性结合于TNFR2的Stefin A蛋白变体或包括该蛋白变体的融合蛋白的核酸中的基因修饰的细胞，及其用途 |
| WO2025250701A1 (en) * | 2024-05-28 | 2025-12-04 | Nektar Therapeutics | Anti-tumor necrosis factor receptor 2 (tnfr2) antibodies and methods of use |
| WO2026022721A1 (en) * | 2024-07-26 | 2026-01-29 | Janssen Biotech, Inc. | Anti-tnfr2 antibodies |
| CN119591710B (zh) * | 2024-11-12 | 2026-01-13 | 澳门大学 | 一种激动性tnfr2单域抗体及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US7628988B2 (en) | 2002-06-27 | 2009-12-08 | The General Hospital Corporation | Methods and compositions for treating type 1 diabetes |
| EP3936137A1 (en) | 2013-02-07 | 2022-01-12 | The General Hospital Corporation | Methods for expansion or depletion of t-regulatory cells |
| CN115043943A (zh) * | 2015-05-15 | 2022-09-13 | 综合医院公司 | 拮抗性抗肿瘤坏死因子受体超家族抗体 |
| US20190135929A1 (en) | 2015-08-28 | 2019-05-09 | The General Hospital Corporation | Agonistic anti-tumor necrosis factor receptor 2 antibodies |
| CA3004830A1 (en) * | 2015-11-11 | 2017-05-18 | Opi Vi- Ip Holdco Llc | Composition and methods for anti-tnfr2 antibodies |
| US11859002B2 (en) * | 2016-05-13 | 2024-01-02 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor 2 antibodies |
-
2019
- 2019-11-01 CN CN202511313289.7A patent/CN121248780A/zh active Pending
- 2019-11-01 MX MX2021005151A patent/MX2021005151A/es unknown
- 2019-11-01 AU AU2019370999A patent/AU2019370999A1/en active Pending
- 2019-11-01 WO PCT/EP2019/080003 patent/WO2020089473A2/en not_active Ceased
- 2019-11-01 CN CN202511313741.XA patent/CN121248781A/zh active Pending
- 2019-11-01 CA CA3117756A patent/CA3117756A1/en active Pending
- 2019-11-01 CN CN201980072437.7A patent/CN112996812B/zh active Active
- 2019-11-01 EP EP19805900.8A patent/EP3873935A2/en active Pending
- 2019-11-01 JP JP2021523958A patent/JP7664833B2/ja active Active
- 2019-11-01 US US17/290,340 patent/US12139547B2/en active Active
- 2019-11-01 BR BR112021008007-4A patent/BR112021008007A2/pt unknown
- 2019-11-01 KR KR1020217014401A patent/KR20210087466A/ko not_active Ceased
-
2021
- 2021-04-27 IL IL282713A patent/IL282713A/en unknown
- 2021-04-30 MX MX2025014435A patent/MX2025014435A/es unknown
-
2024
- 2024-09-16 US US18/886,853 patent/US20250066492A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022514179A5 (https=) | ||
| CN111182919B (zh) | 抗cd137抗体 | |
| Venkataramani et al. | Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP/IL13 bispecific antibodies | |
| JP2022512905A5 (https=) | ||
| CN111183159B (zh) | 靶向cd137的抗体及其使用方法 | |
| JP2024522360A (ja) | 抗ｃｃｒ８抗体及びその使用 | |
| JP7754506B2 (ja) | ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 | |
| JP2024541680A5 (https=) | ||
| CA3192208A1 (en) | Anti-par-2 antibodies and methods of use thereof | |
| JP2023517754A5 (https=) | ||
| CA3099406A1 (en) | Antibodies against lif and dosage forms thereof | |
| JP7570929B2 (ja) | Ｌｉｆを定量化する方法及びその使用 | |
| EP3636320A1 (en) | Antibodies targeting cd137 and methods of use thereof | |
| TWI839395B (zh) | 靶向cd137的抗體及其使用方法 | |
| EP4534562A1 (en) | Bispecific antibody and application thereof | |
| RU2021115563A (ru) | Новые молекулы агонистических анти-tnfr2 антител | |
| WO2019072566A1 (en) | COMBINATION OF ANTI-IL10 AND ANTI-PD1 ANTIBODIES FOR THE TREATMENT OF CANCER | |
| JP7280259B2 (ja) | 非アルコール性脂肪性肝炎の抗ｈｕＴＮＦＲ１治療 | |
| CN113166264B (zh) | 一种分离的抗原结合蛋白及其用途 | |
| HK40121767A (en) | Bispecific antibody and application thereof | |
| JP2018505144A (ja) | 抗ｃｘｃｌ１２抗体分子およびその使用 | |
| TW202600594A (zh) | 結合構築體(一) | |
| AU2024204564A1 (en) | Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer | |
| HK40117648A (zh) | Il-18bp拮抗剂抗体及其在癌症治疗中的单一疗法和组合疗法中的用途 | |
| RU2021115554A (ru) | Новые молекулы антагонистических анти-tnfr2-антител |